All TKIs with promising preclinical and clinical effectiveness against sarcoma, including apatinib, anlotinib, axitinib, imatinib, pazopanib, regorafenib, sorafenib, and sunitinib, target multiple angiogenic and growth-promoting receptor tyrosine kinases, as shown in Table 7. Here, NTRK1 is linked to sarcoma.